Capmatinib (Tabrecta®): A Comprehensive Clinical and Pharmacological Monograph

Executive Summary

Capmatinib is a highly selective, orally bioavailable, adenosine triphosphate (ATP)-competitive inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase. Developed by Novartis, Capmatinib, marketed under the brand name Tabrecta®, represents a significant advancement in the field of precision oncology. Its mechanism of action is centered on the potent and specific inhibition of aberrant MET signaling, a key oncogenic driver in various malignancies. The drug is particularly effective against tumors harboring mutations that lead to MET exon 14 skipping (METex14), a specific genetic alteration that results in a constitutively active and stable MET protein.

Capmatinib was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on May 6, 2020, becoming the first therapy specifically indicated for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a METex14 mutation. This approval was based on compelling efficacy data from the pivotal GEOMETRY mono-1 Phase II clinical trial, which demonstrated substantial and durable tumor responses. In treatment-naïve patients, Capmatinib achieved an overall response rate of 68%, with a median duration of response of 12.6 months. In patients who had received prior therapy, the overall response rate was 41%, with a median duration of response of 9.7 months. These outcomes established a new standard of care for a patient population that previously lacked targeted therapeutic options.

The safety profile of Capmatinib is considered manageable, with the most common adverse events including peripheral edema, nausea, fatigue, and increased blood creatinine. However, clinically significant risks, such as interstitial lung disease/pneumonitis and hepatotoxicity, require careful monitoring and adherence to established dose modification guidelines. This monograph provides an exhaustive review of Capmatinib, encompassing its fundamental chemistry, detailed mechanism of action, comprehensive pharmacokinetic profile, pivotal clinical trial data, safety and tolerability, regulatory journey, and its strategic position within the evolving therapeutic landscape of NSCLC.

---

1.0 Introduction: The MET Pathway and the Advent of Targeted Therapy in NSCLC

1.1 The Oncogenic Role of MET Dysregulation in Non-Small Cell Lung Cancer

The mesenchymal-epithelial transition (MET) proto-oncogene encodes a receptor tyrosine kinase (RTK) known as c-MET, or the hepatocyte growth factor receptor (HGFR).[1] In normal physiological contexts, the c-MET receptor and its exclusive ligand, hepatocyte growth factor (HGF), form a signaling axis that is integral to embryonic development, organogenesis, organ regeneration, and tissue repair.[2] Upon HGF binding, the MET receptor dimerizes and undergoes autophosphorylation, initiating a cascade of downstream signaling pathways critical for cellular proliferation, survival, and motility.

In oncology, the aberrant and uncontrolled activation of the MET pathway serves as a potent oncogenic driver.[2] This dysregulation can occur through several distinct molecular mechanisms, including activating point mutations within the kinase domain, amplification of the

MET gene leading to receptor overexpression, chromosomal translocations, or ligand-mediated autocrine/paracrine loops.[5] Such aberrant signaling leads to the constitutive overactivation of critical downstream effector pathways, including the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), RAS/mitogen-activated protein kinase (RAS/MAPK), and signal transducer and activator of transcription 3 (STAT3) pathways.[2] This sustained signaling promotes tumor growth, invasion, and metastasis.

A particularly significant mechanism of MET dysregulation in non-small cell lung cancer (NSCLC) is the presence of mutations that affect mRNA splicing, leading to the skipping of exon 14 of the MET gene (METex14).[2] This specific genetic alteration is identified in approximately 3% to 4% of patients with NSCLC, most commonly in the adenocarcinoma subtype, and is associated with a poor prognosis.[1] Exon 14 encodes the juxtamembrane domain of the MET receptor, which contains a binding site for the E3 ubiquitin ligase, Casitas B-lineage lymphoma (CBL). The binding of CBL to this domain targets the MET receptor for ubiquitination and subsequent lysosomal degradation. When exon 14 is skipped, this critical degradation signal is lost. The resulting MET protein is more stable, accumulates on the cell surface, and exhibits prolonged, ligand-independent signaling, thereby driving oncogenesis.[1] The identification of this distinct, actionable driver mutation highlighted an urgent unmet medical need for a targeted therapy.

1.2 Capmatinib: Development of a Potent and Selective MET Inhibitor

Capmatinib, also known by its development codes INC280 and INCB28060, is a small molecule kinase inhibitor developed by Novartis (under license from Incyte Corporation) to specifically target the c-MET kinase.[2] The development of Capmatinib was predicated on a precision medicine strategy, aiming to create a highly selective agent for patients whose tumors are dependent on MET signaling.

The rationale for developing a highly selective inhibitor was informed by the challenges faced by earlier, less selective agents. Multi-kinase inhibitors that target MET alongside other kinases, such as vascular endothelial growth factor receptor 2 (VEGFR2), often produce ambiguous clinical results, making it difficult to discern the true contribution of MET inhibition to any observed efficacy.[6] Furthermore, the lack of a stringent, biomarker-based patient selection strategy in early trials hampered the clinical development of MET-targeting agents. Capmatinib was designed to overcome these limitations through its high potency and remarkable selectivity for MET over other kinases. This molecular precision allows for a clear therapeutic hypothesis: in tumors with a defined mechanism of MET activation, such as a

METex14 mutation, selective inhibition of the MET kinase should result in a profound anti-tumor effect. This approach set the stage for Capmatinib to become a landmark therapy, offering the first targeted treatment option for the molecularly defined subset of NSCLC patients with METex14-mutated disease.[1]

The success of Capmatinib validates the "oncogene addiction" model for tumors harboring the METex14 mutation. The discovery that this specific genetic event impairs receptor degradation provides a clear mechanistic basis for MET dependency, creating a distinct molecular vulnerability.[1] Unlike broader biomarkers such as gene amplification, which can be heterogeneous and have varying degrees of biological impact, the

METex14 skipping mutation represents a discrete, functional alteration that is highly predictive of response to a targeted inhibitor. Consequently, the clinical success of Capmatinib underscores the indispensable role of comprehensive molecular profiling, particularly next-generation sequencing (NGS), in routine clinical practice for all patients with advanced NSCLC. Such testing is critical to identify the 3-4% of patients who stand to derive profound and durable benefit from this targeted therapy.[1]

---

2.0 Chemical Profile and Synthesis

2.1 Physicochemical Properties and Structural Elucidation

Capmatinib is a synthetic organic small molecule classified as an imidazotriazine derivative. Its chemical identity is well-defined through a comprehensive set of nomenclature and identifiers.

• Nomenclature and Identifiers:
• Generic Name: Capmatinib [3]
• Brand Name: Tabrecta® [3]
• Development Codes: INC280, INCB28060 [10]
• IUPAC Name: 2-Fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b]triazin-2-yl]benzamide [3]
• CAS Number: 1029712-80-8 (free base) [3]
• DrugBank ID: DB11791 [2]
• PubChem CID: 25145656 [3]
• Molecular and Structural Formulae:
• Molecular Formula: C23​H17​FN6​O [3]
• Molecular Weight: Approximately 412.42 g/mol [3]
• SMILES: CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F [2]
• InChIKey: LIOLIMKSCNQPLV-UHFFFAOYSA-N [3]

The structure of Capmatinib incorporates several key chemical moieties, including a quinoline ring system, a fluorinated benzamide group, and a core imidazo[1,2-b]triazine scaffold, which are crucial for its interaction with the MET kinase active site.[7] A summary of its key physicochemical properties, relevant for its formulation and pharmacokinetic behavior, is presented in Table 1. The molecule adheres to Lipinski's rule of five, predicting good oral bioavailability.[16]

Table 1: Key Physicochemical Properties of Capmatinib

Property	Value	Source
Molecular Formula	C23​H17​FN6​O	3
Molecular Weight	412.42 g/mol	3
IUPAC Name	2-Fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b]triazin-2-yl]benzamide	3
CAS Number	1029712-80-8	3
Water Solubility	0.00529 mg/mL	17
logP	3.04	17
pKa (Strongest Acidic)	12.77	17
pKa (Strongest Basic)	4.55	17
Hydrogen Bond Donors	1	16
Hydrogen Bond Acceptors	5-6	16
Rotatable Bonds	4-5	16
Polar Surface Area	85.07 A˚2	16

2.2 Key Synthetic Pathways

The chemical synthesis of Capmatinib can be accomplished through various routes, often involving the construction of key fragments followed by their coupling. One documented approach involves a late-stage cyclization reaction to form the core imidazo-triazine ring system.[18]

A representative synthesis can be described in three main parts: preparation of a quinoline fragment, preparation of a biaryl fragment, and their final union and modification.[18]

1. Preparation of the Quinoline Fragment: The synthesis begins with acrolein diethyl acetal, which undergoes hydroboration followed by a Suzuki cross-coupling reaction with 6-bromoquinoline. The resulting product is then treated with aqueous acid to unmask an aldehyde functional group. This aldehyde is subsequently converted to a hemiaminal intermediate, which serves as the quinoline-containing building block for the final coupling step.[18]
2. Preparation of the Biaryl Fragment: Concurrently, a biaryl fragment is prepared. This process starts with the condensation of aminoguanidine bicarbonate and glyoxal to form 1,2,4-triazin-3-amine. This intermediate is then brominated. Separately, a boronate coupling partner is synthesized from 4-bromo-2-fluoro-benzonitrile. A Suzuki coupling between the bromo-triazine and the aryl boronate yields the desired biaryl fragment.[18]
3. Final Assembly and Derivatization: The quinoline and biaryl fragments are united via an annulation reaction in warm ethylene glycol to construct the central imidazo-triazine scaffold. The resulting intermediate is hydrolyzed under acidic conditions to yield a carboxylic acid. The final step involves an amidation reaction with methylamine to form the benzamide moiety, followed by treatment with hydrochloric acid to produce Capmatinib as a dihydrochloride salt, the form used in clinical formulations.[18]

An alternative synthetic route starts from 4-bromo-3-fluorobenzoic acid, which is converted to an acyl chloride and then reacted with N,O-dimethylhydroxylamine to form a Weinreb amide. Subsequent reactions involving a Grignard reagent, oxidation, and cycloadditions build the core structure, which is then elaborated through cyanation, hydrolysis, and final amidation to yield Capmatinib.[20] These multi-step syntheses allow for the large-scale production required for clinical and commercial supply.

---

3.0 Clinical Pharmacology

3.1 Mechanism of Action: Selective ATP-Competitive Inhibition of the MET Kinase

Capmatinib is an orally bioavailable, reversible, and ATP-competitive inhibitor of the MET receptor tyrosine kinase.[10] Its mechanism of action is characterized by high potency and exceptional selectivity. In biochemical assays, Capmatinib inhibits the MET kinase with a half-maximal inhibitory concentration (

IC50​) of 0.13 nM, indicating a very strong binding affinity.[10]

The molecular basis for this potent and selective inhibition lies in its specific mode of binding to the ATP-binding pocket of the MET kinase domain. Structural modeling, based on co-crystal structures of similar inhibitors, reveals key interactions. The imidazotriazine core of the Capmatinib molecule engages in an aromatic stacking interaction with the tyrosine residue at position 1230 (Y1230) of the MET kinase.[5] Simultaneously, the quinoline moiety of the drug forms critical interactions with the hinge region of the kinase, a common anchoring point for kinase inhibitors. This specific binding orientation is stabilized by a particular conformation of the kinase's activation loop (A-loop), which is maintained by a salt bridge between residues D1228 and K1110.[5]

This combination of interactions is highly specific to the MET kinase. While some of the interacting residues are conserved in other kinases, the unique A-loop conformation required for high-affinity binding is stabilized by hydrophobic interactions that are specific to MET.[5] This structural specificity is the foundation of Capmatinib's remarkable selectivity. In a broad kinase panel screening, Capmatinib was found to be over 10,000-fold more selective for MET than for a large panel of other human kinases.[4] This high degree of selectivity is a critical pharmacological attribute, as it minimizes off-target activities and their associated toxicities, thereby contributing to a more favorable therapeutic index. By focusing its activity on the intended oncogenic driver, Capmatinib exemplifies the principles of modern targeted drug design, where chemical precision enables a predictable clinical profile and a clear biomarker-driven therapeutic strategy.

3.2 Pharmacodynamics: Suppression of MET Phosphorylation and Downstream Signaling

By competitively blocking the binding of ATP to the MET kinase domain, Capmatinib directly prevents the receptor's autophosphorylation, which is the essential initiating event for signal transduction.[1] This blockade effectively shuts down the aberrant, constitutive signaling that drives tumorigenesis in MET-dependent cancers. The inhibition of MET phosphorylation disrupts the recruitment and activation of downstream signaling proteins, leading to the profound suppression of key pro-survival and pro-proliferative pathways, including the PI3K/AKT, RAS/MAPK, and STAT3/5 signaling cascades.[2]

The pharmacodynamic effects of Capmatinib have been demonstrated in various preclinical models. In MET-dependent cancer cell lines, treatment with Capmatinib leads to a dose-dependent inhibition of MET phosphorylation as well as the phosphorylation of downstream effectors such as AKT, ERK1/2, FAK, GAB1, and STAT3/5.[5] The functional consequences of this signaling blockade are potent anti-tumor effects, including the inhibition of cancer cell proliferation and migration, and the robust induction of apoptosis (programmed cell death).[1]

Crucially, Capmatinib demonstrates potent activity against the specific, abnormal form of the MET protein that results from MET exon 14 skipping.[13] This variant protein, which evades normal degradation pathways, is highly sensitive to inhibition by Capmatinib. The drug's ability to effectively neutralize this constitutively active receptor is the direct pharmacological basis for its clinical efficacy and its specific indication for patients with

METex14-mutated NSCLC.

---

4.0 Pharmacokinetics: A Profile of Systemic Exposure and Disposition

4.1 Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Capmatinib has been characterized in both healthy volunteers and patients with cancer, revealing properties consistent with a viable oral therapeutic agent.

• Absorption: Following oral administration, Capmatinib is absorbed relatively rapidly, with the time to reach maximum plasma concentration (Tmax) occurring at a median of 1 to 2 hours post-dose.[21] Studies in healthy volunteers using radiolabeled Capmatinib estimated the extent of oral absorption to be approximately 49.6%.[23] Over a dose range of 100 to 600 mg twice daily, the drug exhibits generally dose-proportional pharmacokinetics, with both the area under the curve (AUC) and peak concentration (Cmax) increasing predictably with dose.[21] A notable clinical advantage is that its exposure is minimally affected by food intake, allowing for dosing with or without meals.[21]
• Distribution: Capmatinib is extensively distributed throughout the body and into peripheral tissues. This is evidenced by a moderate-to-high apparent volume of distribution (Vz/F) with a geometric mean of 473 L.[23] The drug is highly bound to plasma proteins, with a binding fraction of approximately 96%.[12] A critical aspect of its distribution is its ability to penetrate the central nervous system (CNS). Preclinical studies in rats and monkeys demonstrated significant cerebrospinal fluid (CSF) concentrations, and this is corroborated by clinical evidence from the GEOMETRY mono-1 trial, which showed intracranial responses in patients with brain metastases.[11]
• Metabolism: Capmatinib undergoes extensive metabolism through multiple pathways, including lactam formation, hydroxylation, N-dealkylation, formation of a carboxylic acid, hydrogenation, N-oxygenation, and glucuronidation.[23] The two primary enzyme systems responsible for its metabolism are cytochrome P450 3A4 (CYP3A4) and aldehyde oxidase (AO).[15] The most abundant circulating metabolite, designated M16, is formed via imidazo-triazinone formation (a lactam formation reaction), which is catalyzed mainly by cytosolic aldehyde oxidase.[23] The involvement of CYP3A4 in its hepatic microsomal metabolism is also significant and forms the basis for several clinically relevant drug-drug interactions.[24] This dual metabolic pathway provides a degree of metabolic redundancy. While interactions with strong modulators of CYP3A4 are clinically significant and require management, the parallel clearance pathway via aldehyde oxidase may help to mitigate the magnitude of these interactions compared to drugs that rely solely on a single CYP enzyme for their elimination.
• Excretion: The elimination of Capmatinib and its metabolites occurs primarily through metabolism followed by biliary/fecal and renal excretion. In a human mass balance study, the excretion of radioactivity was complete within 7 days of a single oral dose.[23] The apparent mean elimination half-life ( t1/2​) of Capmatinib in plasma is relatively short, reported to be between 6.5 and 7.8 hours.[21] This faster clearance profile minimizes the potential for drug accumulation with twice-daily dosing and may contribute to a more manageable safety profile.[21]

Table 2: Summary of Capmatinib Pharmacokinetic Parameters

Parameter	Value	Source
Tmax (median, h)	1.09 - 2.0	21
Cmax (steady state, ng/mL)	4,780	21
AUC (0-t, steady state, ng·h/mL)	20,200	21
Elimination Half-life (t1/2​, h)	6.54 - 7.84	21
Apparent Volume of Distribution (Vz/F, L)	473	23
Oral Absorption (%)	~49.6	23
Protein Binding (%)	~96	12
Primary Metabolic Enzymes	CYP3A4, Aldehyde Oxidase	15

---

5.0 Clinical Efficacy: Evidence from the GEOMETRY mono-1 Trial

5.1 Study Design and Patient Population

The clinical efficacy of Capmatinib in patients with MET-dysregulated NSCLC was established in the pivotal GEOMETRY mono-1 study (NCT02414139).[13] This was a Phase II, multicenter, non-randomized, open-label, multi-cohort trial designed to evaluate the safety and efficacy of Capmatinib monotherapy.[28]

The study enrolled adult patients with locally advanced or metastatic (Stage IIIB or IV) NSCLC. A key eligibility criterion was the confirmation of MET dysregulation, defined as either a mutation leading to MET exon 14 skipping or MET gene amplification.[8] Patients were also required to have wild-type status for the epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) gene, ensuring that the observed efficacy could be attributed to the inhibition of MET signaling rather than other known oncogenic drivers.[26]

Participants were prospectively assigned to one of several cohorts based on their specific MET alteration and their prior lines of systemic therapy.[8] This report focuses on the cohorts of patients with

METex14-mutated NSCLC, which formed the basis for the drug's regulatory approvals. All patients in these cohorts received Capmatinib at a dose of 400 mg administered orally twice daily until disease progression or unacceptable toxicity.[8]

The primary efficacy endpoint of the study was the overall response rate (ORR), defined as the proportion of patients with a confirmed complete or partial response. This was assessed by a Blinded Independent Review Committee (BIRC) according to the Response Evaluation Criteria in Solid Tumours, version 1.1 (RECIST v1.1).[26] Key secondary endpoints included the duration of response (DOR), progression-free survival (PFS), and overall survival (OS).[13]

5.2 Efficacy in Treatment-Naïve Patients with METex14 NSCLC

The efficacy of Capmatinib as a first-line therapy was evaluated in treatment-naïve patients enrolled in Cohorts 5b and 7 of the GEOMETRY mono-1 trial. The results demonstrated a high level of anti-tumor activity in this population.

In the initial analysis presented for regulatory approval, which included 28 treatment-naïve patients, the ORR confirmed by BIRC was 68% (95% Confidence Interval [CI], 48–84).[8] The responses were durable, with a median DOR of 12.6 months (95% CI, 5.6–not estimable).[11] Subsequent data from expansion cohorts reinforced these robust findings, with Cohort 7 showing a consistent ORR of 65.6%.[28]

The final, mature analysis of the pooled treatment-naïve population, comprising 60 patients, confirmed these outcomes. The BIRC-assessed ORR was 68% (95% CI, 55.0–79.7).[31] The mature data also provided insight into long-term survival, with a clinically meaningful median OS of 20.8 months (95% CI, 12.4–not estimable) observed in Cohort 5b.[28]

5.3 Efficacy in Previously Treated Patients with METex14 NSCLC

The trial also established the efficacy of Capmatinib in patients with METex14-mutated NSCLC who had progressed on prior systemic therapy (Cohorts 4 and 6). The majority of these patients had received at least one prior line of platinum-based chemotherapy.[9]

In this more heavily pre-treated population, Capmatinib still demonstrated substantial anti-tumor activity. The initial analysis of 69 previously treated patients showed a BIRC-confirmed ORR of 41% (95% CI, 29–53).[8] The responses remained durable, with a median DOR of 9.7 months (95% CI, 5.6–13.0).[11]

The final analysis of the full previously treated population, which included 100 patients, showed a consistent BIRC-assessed ORR of 44% (95% CI, 34.1–54.3).[31] The mature median OS in this refractory setting was 13.6 months (95% CI, 8.6–22.2), a significant outcome for this patient group with limited options.[28]

The marked difference in efficacy between the first-line and previously treated settings (ORR of 68% vs. 44%) is a critical clinical finding. This disparity is not likely due to patient selection, as all patients had the target mutation. Instead, it strongly suggests that tumors develop additional resistance mechanisms and become less dependent on the MET signaling pathway after being subjected to the selective pressure of prior therapies, such as cytotoxic chemotherapy. This biological evolution likely involves the activation of parallel or downstream signaling pathways that can bypass the MET blockade. This observation has profound implications for clinical practice, providing a strong, evidence-based rationale for performing comprehensive molecular testing at the time of initial diagnosis and prioritizing the use of Capmatinib as a first-line therapy whenever a METex14 mutation is identified. Delaying this targeted therapy to later lines appears to significantly diminish its potential benefit, depriving patients of the best possible clinical outcome.

5.4 Intracranial Efficacy in Patients with Brain Metastases

A key challenge in the treatment of metastatic NSCLC is the management of brain metastases. A post-hoc analysis of the GEOMETRY mono-1 trial evaluated the intracranial activity of Capmatinib in 13 evaluable patients who had brain metastases at baseline. The analysis revealed 7 intracranial responses, which included 4 complete responses.[11] This demonstration of CNS activity is clinically significant and aligns with preclinical pharmacokinetic data suggesting that Capmatinib can effectively cross the blood-brain barrier.[21]

Table 3: Efficacy Outcomes from the GEOMETRY mono-1 Trial (METex14 Cohorts)

Efficacy Endpoint	Treatment-Naïve Patients (N=60)	Previously Treated Patients (N=100)
ORR by BIRC (%)	68 (95% CI, 55.0–79.7)	44 (95% CI, 34.1–54.3)
Median DOR by BIRC (months)	12.6 (95% CI, 5.6–NE)	9.7 (95% CI, 5.6–13.0)
Median OS (months)	20.8 (95% CI, 12.4–NE)*	13.6 (95% CI, 8.6–22.2)†
Data from Cohort 5b; NE = Not Estimable. †Data from Cohort 4.
Sources: 11

---

6.0 Safety and Tolerability Profile

6.1 Analysis of Common and Serious Adverse Events (AEs)

The safety profile of Capmatinib has been extensively evaluated in the GEOMETRY mono-1 study across all cohorts (N=373) and is generally considered manageable with appropriate monitoring and intervention.[8] Adverse events of any grade were reported in nearly all patients (98.4%).[28]

• Most Common Adverse Events: The most frequently reported AEs (occurring in ≥20% of patients) are consistent across studies and include peripheral edema, gastrointestinal toxicities, fatigue, and renal function changes. Specific incidences from the overall safety population are:
• Peripheral edema: 43% - 54% [11]
• Nausea: 34% - 45% [11]
• Fatigue/Asthenia: 22% - 32% [22]
• Vomiting: 19% - 28% [11]
• Dyspnea (shortness of breath): 23% - 24% [22]
• Decreased appetite: 21% [22]
• Increased blood creatinine: 18% - 26.5% [22]
• Serious Adverse Events (SAEs): A significant proportion of patients experienced Grade 3 or 4 AEs, with rates reported between 44% and 68.6%.[28] The most common Grade 3/4 SAE was dyspnea.[31] Treatment-related deaths occurred in 1% of patients and were attributed to events such as pneumonitis, organizing pneumonia, hepatitis, and cardiac arrest.[31]
• Dose Modifications and Discontinuation: Adverse events are a frequent cause for dose adjustments. Dose interruptions or reductions were required in 26% to 57% of patients, with peripheral edema and biochemical abnormalities (liver and renal) being the most common triggers.[34] Approximately 16% of patients had to permanently discontinue Capmatinib due to treatment-related AEs.[28]

The high incidence of peripheral edema, affecting approximately half of all patients, is notable. This toxicity is also observed with other selective MET inhibitors, suggesting it is a mechanism-based "class effect".[38] The HGF/MET signaling pathway plays a physiological role in maintaining the integrity and permeability of the vascular endothelium.[37] Potent inhibition of this pathway may disrupt this function, leading to fluid extravasation into the interstitial space, which manifests clinically as edema. Because this side effect is mechanistically linked to the drug's intended target, it is unlikely to be circumvented by future MET inhibitors. This underscores the critical importance of proactive clinical management—including patient education, use of compression stockings, and appropriate dose modifications—to allow patients to remain on this effective therapy.[37]

6.2 In-Depth Review of Warnings and Precautions

The prescribing information for Capmatinib includes several important warnings and precautions for potentially severe adverse reactions. While the drug does not carry a black box warning in the United States, these risks require vigilant monitoring.[40]

• Interstitial Lung Disease (ILD) / Pneumonitis: This is a serious and potentially fatal pulmonary toxicity. Patients should be monitored for new or worsening respiratory symptoms such as cough, dyspnea, or fever. If ILD/pneumonitis is suspected, Capmatinib must be immediately withheld. If the diagnosis is confirmed, the drug should be permanently discontinued.[3]
• Hepatotoxicity: Capmatinib can cause liver injury, manifesting as elevations in serum aminotransferases (ALT, AST) and total bilirubin. Liver function tests must be monitored at baseline, every 2 weeks for the first 3 months of treatment, and then monthly or as clinically indicated. Specific, grade-based guidelines are provided for dose modification, interruption, or permanent discontinuation in the event of hepatotoxicity.[3]
• Photosensitivity: Preclinical studies indicated a risk of photosensitivity reactions. Patients should be advised to limit direct ultraviolet exposure by using broad-spectrum sunscreen (SPF 30 or higher) and wearing protective clothing during treatment.[3]
• Embryo-Fetal Toxicity: Based on its mechanism of action and findings in animal studies, Capmatinib can cause harm to a developing fetus. The pregnancy status of females of reproductive potential must be verified before initiating treatment. Both male and female patients of reproductive potential must use effective contraception during treatment and for 1 week after the final dose.[3]
• Pancreatic Toxicity: Increases in serum amylase and lipase levels have been observed. Cases of acute pancreatitis have been reported, requiring monitoring for signs and symptoms such as abdominal pain, nausea, and vomiting.[12]

Table 4: Common and Serious Adverse Events Associated with Capmatinib (GEOMETRY mono-1, N=373)

Adverse Event (by System Organ Class)	All Grades (%)	Grade 3-4 (%)
General Disorders
Peripheral Edema	54.2	10.2*
Fatigue/Asthenia	22.3	4.0*
Pyrexia (Fever)	14.0	0.8*
Gastrointestinal Disorders
Nausea	45.0	2.7
Vomiting	28.2	1.9
Diarrhea	18.0	1.6
Metabolism and Nutrition Disorders
Decreased Appetite	21.2	1.9
Respiratory, Thoracic and Mediastinal Disorders
Dyspnea	23.3	5.0
Cough	16.0	0.3
ILD/Pneumonitis	Common (1-10%)	-
Investigations
Blood Creatinine Increased	26.5	1.6
Alanine Aminotransferase (ALT) Increased	Common (1-10%)	-
Aspartate Aminotransferase (AST) Increased	Common (1-10%)	-
Grade 3-4 data for some AEs were not explicitly separated in all sources; percentages reflect the most comprehensive data available.
Sources: 22

---

7.0 Dosing, Administration, and Clinical Management

7.1 Approved Dosing Regimen and Administration Guidelines

The clinical use of Capmatinib is guided by a well-defined dosing and administration schedule designed to optimize efficacy while allowing for management of potential toxicities.

• Recommended Dose: The standard recommended starting dose of Capmatinib is 400 mg taken orally twice daily.[13]
• Formulations: Capmatinib is supplied as 150 mg and 200 mg film-coated tablets. The 400 mg starting dose is typically administered as two 200 mg tablets per dose.[13]
• Administration with Food: The medication can be taken with or without food, providing flexibility for patients.[13]
• Method of Administration: Patients should be instructed to swallow the tablets whole. The tablets must not be broken, crushed, or chewed, as this can alter the drug's release profile.[42]
• Management of Missed or Vomited Doses: If a dose is missed or if the patient vomits after taking a dose, they should not take a replacement dose. Instead, they should wait and take the next dose at its regularly scheduled time. This prevents potential overdose from taking two doses too close together.[42]

7.2 Evidence-Based Recommendations for Dose Modification and Management of Toxicities

To manage adverse reactions, a structured dose reduction strategy is recommended. This approach allows for the continuation of therapy at a more tolerable dose level, which is crucial for maintaining clinical benefit.

• Dose Reduction Schedule:
• First Dose Reduction: Reduce the dose to 300 mg orally twice daily (administered as two 150 mg tablets).[42]
• Second Dose Reduction: Further reduce the dose to 200 mg orally twice daily (administered as one 200 mg tablet).[45]
• Discontinuation Threshold: If a patient is unable to tolerate a dose of 200 mg twice daily, treatment with Capmatinib should be permanently discontinued.[42]

Specific, detailed recommendations for dose modification are provided for key adverse reactions, translating safety data into actionable clinical guidance. These guidelines are essential for ensuring patient safety and are summarized in Table 5.

Table 5: Dose Modification Guidelines for Key Adverse Reactions

Adverse Reaction	Severity (Grade)	Recommended Action
Interstitial Lung Disease (ILD)/Pneumonitis	Any Grade	Permanently discontinue Capmatinib.
Increased ALT and/or AST without increased total bilirubin	Grade 3 (>5 to ≤20 x ULN)	Withhold until recovery to baseline. If recovered ≤7 days, resume at same dose. If >7 days, resume at a reduced dose.
	Grade 4 (>20 x ULN)	Permanently discontinue Capmatinib.
Increased ALT/AST (>3 x ULN) with increased total bilirubin (>2 x ULN)	Any	Permanently discontinue Capmatinib.
Increased total bilirubin without concurrent increased ALT/AST	Grade 2 (>1.5 to ≤3 x ULN)	Withhold until recovery to baseline. If recovered ≤7 days, resume at same dose. If >7 days, resume at a reduced dose.
	Grade 3 (>3 to ≤10 x ULN)	Withhold until recovery to baseline. If recovered ≤7 days, resume at reduced dose. Otherwise, permanently discontinue.
	Grade 4 (>10 x ULN)	Permanently discontinue Capmatinib.
Other Adverse Reactions	Grade 2	Maintain dose. If intolerable, consider withholding until resolved, then resume at a reduced dose.
	Grade 3	Withhold until resolved, then resume at a reduced dose.
	Grade 4	Permanently discontinue Capmatinib.
ULN = Upper Limit of Normal. Sources: 42

---

8.0 Drug Interaction Profile

8.1 Interactions Mediated by CYP450 Enzymes and Transporter Proteins

The pharmacokinetic profile of Capmatinib makes it susceptible to and a perpetrator of several clinically significant drug-drug interactions. Its metabolism is primarily mediated by CYP3A4 and aldehyde oxidase, and it also interacts with key drug transporter proteins.[15]

• Capmatinib as a Victim of Interactions (Effects of Other Drugs on Capmatinib):
• CYP3A4 Substrate: As a substrate of CYP3A4, Capmatinib's plasma concentrations can be significantly altered by co-administered CYP3A4 modulators.[34]
• Strong CYP3A Inhibitors: Co-administration with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, grapefruit juice) is expected to increase the exposure (AUC) of Capmatinib. This can heighten the risk and severity of adverse reactions. Close monitoring for Capmatinib-related toxicities is warranted when these combinations are unavoidable.[43]
• Strong and Moderate CYP3A Inducers: Co-administration with strong or moderate CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can substantially decrease Capmatinib's plasma concentrations, potentially leading to a loss of efficacy. The concomitant use of these agents with Capmatinib should be avoided.[43]
• Capmatinib as a Perpetrator of Interactions (Effects of Capmatinib on Other Drugs):
• Inhibitor of Transporters and Enzymes: Capmatinib has been shown to be an inhibitor of several important enzymes and drug transporters, including CYP1A2, P-glycoprotein (P-gp), and Breast Cancer Resistance Protein (BCRP).[43]
• This inhibitory activity means that Capmatinib can increase the plasma concentrations of co-administered drugs that are substrates of these pathways. This can lead to increased toxicity of the co-administered drug.

8.2 Clinically Significant Interactions and Management Recommendations

The bidirectional and complex interaction profile of Capmatinib necessitates careful medication review for every patient. A patient with NSCLC is often older and may have multiple comorbidities, such as hyperlipidemia or cardiovascular disease, making polypharmacy common. The potential for interaction with frequently prescribed medications like statins is therefore high. For instance, many statins (e.g., atorvastatin, rosuvastatin) are substrates of P-gp or BCRP.[46] Co-administration with Capmatinib could increase statin levels, elevating the risk of statin-related myopathy. This is not a theoretical concern but a probable clinical scenario that requires proactive management, such as switching to a different statin or implementing more intensive monitoring for muscle-related symptoms.

• Specific Drug Classes of Concern:
• Statins: Increased risk of side effects from statins like atorvastatin, rosuvastatin, and simvastatin.[46]
• Caffeine: Capmatinib can increase the blood levels and effects of caffeine. Dose adjustment or monitoring may be needed.[46]
• Certain Antifungals (Azoles): As strong CYP3A inhibitors, they can increase Capmatinib levels.[46]
• Certain HIV Drugs: Can act as either inhibitors or inducers of CYP3A, affecting Capmatinib levels.[46]
• P-gp Substrates with a Narrow Therapeutic Index: Co-administration with drugs like digoxin should be approached with caution, and dose adjustments of the P-gp substrate may be necessary.[43]
• Food and Lifestyle Interactions:
• Grapefruit: Patients should avoid consuming grapefruit and grapefruit juice, as they are strong inhibitors of CYP3A4 and can increase Capmatinib exposure.[46]
• Disease State Interactions:
• Caution is advised when using Capmatinib in patients with pre-existing severe liver, lung, or renal dysfunction, as these conditions may exacerbate drug-related toxicities.[47]

---

9.0 Regulatory Status and Comparative Analysis

9.1 Global Regulatory Approvals and the Role of Companion Diagnostics

Capmatinib has achieved regulatory approval in major global markets, marking a significant milestone in the treatment of METex14-mutated NSCLC.

• United States (FDA): On May 6, 2020, the U.S. FDA granted accelerated approval to Capmatinib for the treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping.[2] This was a landmark decision, as Capmatinib became the first therapy specifically approved by the FDA for this molecularly defined patient population.[3] The accelerated approval was based on the compelling ORR and DOR data from the GEOMETRY mono-1 trial. As is standard for this pathway, its continued approval is contingent upon the verification of clinical benefit in confirmatory trials.[2]
• European Union (EMA): Following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 22, 2022, the European Commission granted marketing authorization for Capmatinib in September 2022.[3] The indication in the European Union is more specific, authorizing Capmatinib as a monotherapy for adult patients with advanced NSCLC harboring METex14 skipping alterations who require systemic therapy following prior treatment with immunotherapy, platinum-based chemotherapy, or both.[1]
• Companion Diagnostics: A crucial aspect of Capmatinib's approval and clinical implementation is its link to a companion diagnostic test. The FDA approval is contingent on the detection of the METex14 skipping mutation by an FDA-approved test.[13] Concurrently with the drug's approval, the FDA also approved the FoundationOne CDx (F1CDx) assay as a companion diagnostic to identify patients eligible for Capmatinib treatment.[2] This tight integration of a specific therapy with a validated diagnostic test epitomizes the principles of precision medicine and ensures that the drug is directed to the patient population most likely to benefit.

9.2 Comparative Assessment: Capmatinib versus Tepotinib in METex14 NSCLC

Shortly after Capmatinib's approval, another selective MET inhibitor, Tepotinib (Tepmetko®), also received regulatory approval for the same indication, creating a choice for clinicians. While no head-to-head randomized trials have been conducted, a comparative assessment can be made based on data from their respective pivotal trials (GEOMETRY mono-1 for Capmatinib and VISION for Tepotinib) and other differentiating features.

• Efficacy: In the critical first-line setting, Capmatinib demonstrated a numerically higher ORR in the GEOMETRY mono-1 trial (68%) compared to the ORR reported for the treatment-naïve cohort in the VISION trial for Tepotinib (~57%).[27] In the previously treated setting, the ORRs are more comparable (Capmatinib: 44%; Tepotinib: ~45%).[31] While cross-trial comparisons must be interpreted with caution due to potential differences in patient populations and study conduct, the higher first-line ORR for Capmatinib is a point of discussion among clinicians.[51]
• Dosing and Administration: A key practical difference lies in the dosing regimen. Capmatinib is administered as 400 mg twice daily, requiring patients to take four tablets per day (two tablets, twice a day). In contrast, Tepotinib is administered as 450 mg once daily with food, requiring two tablets per day.[39] The simpler once-daily regimen of Tepotinib may offer a convenience advantage and potentially improve patient adherence.[50]
• Safety Profile: Both drugs exhibit a similar safety profile, dominated by class effects characteristic of MET inhibition. Peripheral edema is a prominent adverse event for both Capmatinib and Tepotinib.[33] Real-world comparative data have shown no statistically significant differences in the overall frequency of key adverse events between the two drugs, although rates of dose reduction and discontinuation due to toxicity may vary.[38]
• Companion Diagnostic: As previously noted, Capmatinib's FDA label is linked to an approved companion diagnostic (F1CDx), providing a standardized method for patient selection.[55] The label for Tepotinib does not specify an FDA-approved test, which offers more flexibility in testing methods but less standardization.[39]

Table 6: Comparative Profile of Capmatinib and Tepotinib in METex14 NSCLC

Feature	Capmatinib (Tabrecta®)	Tepotinib (Tepmetko®)
Dosing Regimen	400 mg orally twice daily	450 mg orally once daily (with food)
Pivotal Trial	GEOMETRY mono-1	VISION
ORR (Treatment-Naïve)	68%	57%
ORR (Previously Treated)	44%	45%
Median DOR (Treatment-Naïve)	12.6 months	46.4 months*
FDA-Approved Companion Diagnostic	Yes (FoundationOne CDx)	No
Key Shared AEs (Class Effects)	Peripheral edema, Hepatotoxicity, Nausea, Fatigue	Peripheral edema, Hepatotoxicity, Nausea, Fatigue
Long-term follow-up data from VISION trial showed extended DOR.
Sources: 31

---

10.0 Mechanisms of Resistance and Future Directions

10.1 Elucidation of Acquired Resistance Pathways

While Capmatinib induces profound and often durable responses in patients with METex14-mutated NSCLC, the eventual development of acquired resistance is a significant clinical challenge.[4] Research into the molecular mechanisms underlying this resistance has revealed predictable patterns of tumor evolution, primarily involving the activation of bypass signaling pathways that restore downstream pro-survival signals.

The cancer cell, when faced with the selective pressure of a potent MET blockade, can adapt by co-opting alternative signaling inputs to reactivate the core PI3K/AKT and RAS/MAPK pathways. This process of oncogenic signaling plasticity is a hallmark of resistance to targeted therapies. In vitro studies using Capmatinib-resistant NSCLC cell lines have robustly identified several key mechanisms:

• Bypass Signaling via EGFR Activation: The most prominent mechanism of acquired resistance is the activation of the Epidermal Growth Factor Receptor (EGFR) signaling pathway. This can occur through several means, including increased expression of EGFR and its ligands (e.g., HBEGF) or the formation of MET-EGFR heterodimers. In these scenarios, the tumor cell effectively switches its dependency from MET to EGFR to maintain downstream signaling and cell survival.[4]
• Activation of Downstream Effectors: Resistance can also arise from genetic alterations in components of the signaling pathways downstream of the MET receptor. The amplification of the PIK3CA gene, which encodes the catalytic subunit of PI3K, has been identified as a key resistance mechanism. PIK3CA amplification leads to constitutive activation of the PI3K/AKT pathway, rendering the cell independent of upstream receptor tyrosine kinase signaling from either MET or EGFR.[4]
• Concurrent Oncogenic Drivers: In some cases, resistance may be primary (present at the start of therapy) rather than acquired. This can be driven by the co-occurrence of other potent oncogenic alterations. For example, concurrent amplification of the MYC oncogene has been implicated in a case of primary resistance to Capmatinib in a patient with a highly MET-amplified tumor.[59]

10.2 Potential Strategies to Overcome Resistance and Areas for Future Investigation

Understanding the mechanisms of resistance provides a rational basis for developing strategies to overcome or delay it. The predictable nature of these escape pathways offers a roadmap for subsequent lines of therapy.

• Rational Combination Therapies: The most promising approach is the use of combination therapies that simultaneously block both the primary driver and the emerging resistance pathway.
• For resistance mediated by EGFR activation, combining Capmatinib with an EGFR tyrosine kinase inhibitor (such as afatinib or osimertinib) has shown synergistic anti-tumor activity in preclinical models.[4]
• In cases of resistance driven by PIK3CA amplification, a dual combination may be insufficient. A triple combination therapy targeting MET, EGFR, and PI3Kα may be necessary to fully suppress the reactivated survival signals.[56]
• Dynamic Monitoring and Adaptive Therapy: The evolution of resistance is a dynamic process. The use of serial liquid biopsies (circulating tumor DNA analysis) offers a non-invasive method to monitor for the emergence of resistance mutations in real-time. This information could guide the timely introduction of a second agent or a switch in therapy before overt clinical progression occurs.
• Future Research: Ongoing and future investigations will continue to explore these combination strategies in clinical trials. Additionally, research is focused on Capmatinib's role in a different context: overcoming acquired resistance to other targeted therapies. In EGFR-mutant or ALK-rearranged NSCLC, MET amplification is a known mechanism of resistance to EGFR and ALK inhibitors, respectively. In this setting, adding Capmatinib to the original targeted therapy is a rational strategy to re-sensitize the tumor to treatment.[5]

---

11.0 Expert Conclusion and Clinical Perspective

Capmatinib (Tabrecta®) represents a paradigm of successful, biomarker-driven drug development in modern oncology. Its approval has fundamentally changed the treatment landscape for the 3-4% of patients with metastatic non-small cell lung cancer whose tumors are driven by MET exon 14 skipping mutations. By providing a highly effective and specific targeted therapy, Capmatinib has established a new standard of care for a patient population that previously had to rely on the limited efficacy and significant toxicity of conventional chemotherapy.

The pivotal data from the GEOMETRY mono-1 trial unequivocally establish the clinical benefit of Capmatinib. The high overall response rate of 68% and the durable median response duration of over a year in the treatment-naïve setting are particularly compelling. These results strongly advocate for the prioritization of Capmatinib as the first-line standard of care for this molecularly defined subset of NSCLC. The significant drop-off in efficacy observed in previously treated patients serves as a powerful reminder of the importance of the therapeutic window of opportunity; delaying targeted therapy diminishes its ultimate impact. Therefore, the key to unlocking the full potential of Capmatinib lies in the universal implementation of comprehensive, upfront molecular testing for all patients newly diagnosed with metastatic NSCLC.

While highly effective, the clinical management of patients on Capmatinib requires diligence. The safety profile is generally manageable, but clinicians must be vigilant in monitoring for and managing characteristic toxicities, most notably peripheral edema, hepatotoxicity, and the rare but serious risk of interstitial lung disease. Proactive patient education and adherence to established dose modification guidelines are essential for maintaining patients on therapy and preserving their quality of life. Furthermore, the complex, bidirectional drug interaction profile necessitates a thorough medication review by clinicians and pharmacists to avoid adverse outcomes.

Looking forward, the primary challenge in the field is the inevitable emergence of acquired resistance. The elucidation of key resistance mechanisms, such as bypass signaling through EGFR and downstream activation of the PI3K pathway, provides a clear direction for future research. The development of rational combination therapies and the use of dynamic monitoring tools like liquid biopsies will be crucial for extending the benefits of MET inhibition. In conclusion, Capmatinib is a transformative therapy that has delivered on the promise of precision medicine for patients with METex14-mutated NSCLC, while simultaneously paving the way for the next generation of strategies to combat therapeutic resistance.

Works cited

1. Optimizing treatment strategies for a MET exon 14 skipping mutation in non-small-cell lung cancer: a case report of sequential immunotherapy and targeted therapy and literature review | Grodkiewicz | Oncology in Clinical Practice, accessed August 21, 2025, https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/96170
2. DrugDevCovid19 - Yang Cao Lab, accessed August 21, 2025, http://cadd.labshare.cn/covid/php/database_candidate.php?id=25145656&rec=DHODH&site=Catalytic%20pocket
3. Capmatinib - Wikipedia, accessed August 21, 2025, https://en.wikipedia.org/wiki/Capmatinib
4. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer ..., accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6639226/
5. Capmatinib (INC280) Is Active Against Models of Non–Small Cell ..., accessed August 21, 2025, https://aacrjournals.org/clincancerres/article/25/10/3164/10723/Capmatinib-INC280-Is-Active-Against-Models-of-Non
6. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET - AACR Journals, accessed August 21, 2025, https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-18-2814/2119300/1078-0432_ccr-18-2814v1.pdf
7. Capmatinib | C23H17FN6O | CID 25145656 - PubChem, accessed August 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Capmatinib
8. Capmatinib Shows Antitumor Activity in Advanced NSCLC with a MET exon 14 Skipping Mutation - CancerNetwork, accessed August 21, 2025, https://www.cancernetwork.com/view/capmatinib-shows-antitumor-activity-in-advanced-nsclc-with-a-met-exon-14-skipping-mutation
9. Durable Responses With Capmatinib in Certain MET-Mutated NSCLC Patients, accessed August 21, 2025, https://www.cancernetwork.com/view/durable-responses-capmatinib-certain-met-mutated-nsclc-patients
10. Capmatinib | INC280 | INCB028060 | CAS#1029712-80-8 | c-Met inhibitor, accessed August 21, 2025, https://www.medkoo.com/products/4674
11. Novartis announces NEJM publication of pivotal study of Tabrecta™ in patients with METex14 metastatic non-small cell lung cancer, accessed August 21, 2025, https://www.novartis.com/news/media-releases/novartis-announces-nejm-publication-pivotal-study-tabrectatm-patients-metex14-metastatic-non-small-cell-lung-cancer
12. Capmatinib | 1029712-80-8 - ChemicalBook, accessed August 21, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB92574678.htm
13. Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation, accessed August 21, 2025, https://ahdbonline.com/issues/2021/december-2021-twelfth-annual-payers-guide/tabrecta-capmatinib-first-fda-approved-drug-for-metastatic-nsclc-with-met-exon-14-skipping-mutation
14. en.wikipedia.org, accessed August 21, 2025, https://en.wikipedia.org/wiki/Capmatinib#:~:text=Capmatinib%2C%20sold%20under%20the%20brand,for%20the%20membrane%20receptor%20HGFR.
15. Capmatinib (INC280) | c-MET Kinase Inhibitor | MedChemExpress, accessed August 21, 2025, https://www.medchemexpress.com/INCB28060.html
16. capmatinib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 21, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7904
17. Capmatinib hydrochloride | DrugBank Online, accessed August 21, 2025, https://go.drugbank.com/salts/DBSALT002950
18. Synthesis of Capmatinib Dihydrocholride - ChemicalBook, accessed August 21, 2025, https://www.chemicalbook.com/article/synthesis-of-capmatinib-dihydrocholride.htm
19. Capmatinib synthesis - chemicalbook, accessed August 21, 2025, https://www.chemicalbook.com/synthesis/capmatinib.htm
20. SYNTHESIS AND DEVELOPMENT OF ANTICANCER DRUG CAPMATINIB - IRJMETS, accessed August 21, 2025, https://www.irjmets.com/uploadedfiles/paper//issue_1_january_2025/66084/final/fin_irjmets1736511523.pdf
21. The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review, accessed August 21, 2025, https://tlcr.amegroups.org/article/view/103369/html
22. Tabrecta | European Medicines Agency (EMA), accessed August 21, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta
23. (PDF) Absorption, Distribution, Metabolism, and Excretion (ADME) of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite - ResearchGate, accessed August 21, 2025, https://www.researchgate.net/publication/342953489_Absorption_Distribution_Metabolism_and_Excretion_ADME_of_Capmatinib_INC280_in_Healthy_Male_Volunteers_and_In_Vitro_Aldehyde_Oxidase_Phenotyping_of_the_Major_Metabolite
24. Absorption, Distribution, Metabolism, and Excretion of Capmatinib ..., accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/32665418/
25. The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/40799414/
26. Capmatinib in MET Exon 14–Mutated Advanced NSCLC (GEOMETRY Mono-1 Study), accessed August 21, 2025, https://www.oncpracticemanagement.com/conference-correspondent/capmatinib-in-met-exon-14-mutated-advanced-nsclc-geometry-mono-1-study
27. GEOMETRY Mono-1 Results: Capmatinib for the Treatment of MET Exon 14–Mutated NSCLC, accessed August 21, 2025, https://jhoponline.com/special-issues/2020-year-in-review-non-small-cell-lung-cancer/geometry-mono-1-results-capmatinib-for-the-treatment-of-met-exon-14-mutated-nsclc
28. Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study. | Request PDF - ResearchGate, accessed August 21, 2025, https://www.researchgate.net/publication/352084402_Capmatinib_in_MET_exon_14-mutated_advanced_NSCLC_Updated_results_from_the_GEOMETRY_mono-1_study
29. GEOMETRY Mono-1 Study: Capmatinib in MET Exon 14–Mutated or MET-Amplified NSCLC, accessed August 21, 2025, https://jons-online.com/special-issues-and-supplements/2020/2020-year-in-review-nsclc/geometry-mono-1-study-capmatinib-in-met-exon-14-mutated-or-met-amplified-nsclc
30. Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) | ClinicalTrials.gov, accessed August 21, 2025, https://clinicaltrials.gov/study/NCT02414139
31. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/39362249/
32. EU approves new blood and lung cancer drugs | MDedge - The Hospitalist, accessed August 21, 2025, https://blogs.the-hospitalist.org/content/eu-approves-new-blood-and-lung-cancer-drugs
33. Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study. - ASCO, accessed August 21, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT342283
34. Capmatinib - LiverTox - NCBI Bookshelf, accessed August 21, 2025, https://www.ncbi.nlm.nih.gov/books/n/livertox/Capmatinib/
35. A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database - PMC - PubMed Central, accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11789861/
36. Capmatinib Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 21, 2025, https://www.drugs.com/sfx/capmatinib-side-effects.html
37. Profile of capmatinib for the treatment of metastatic NSCLC | CMAR - Dove Medical Press, accessed August 21, 2025, https://www.dovepress.com/profile-of-capmatinib-for-the-treatment-of-metastatic-non-small-cell-l-peer-reviewed-fulltext-article-CMAR
38. Real-world outcomes comparison between the MET inhibitors (METi) capmatinib and tepotinib in patients with stage IV non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation. - ASCO Publications, accessed August 21, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e20588
39. Dosing and Treatment Management Guide - TEPMETKO (tepotinib), accessed August 21, 2025, https://www.tepmetko.com/content/dam/web/healthcare/clinicaltrial/oncology/tepmetko/documents/TEPMETKO-Dosing-and-Treatment-Management-Guide.pdf
40. Box Warnings | OncoLink, accessed August 21, 2025, https://www.oncolink.org/cancer-treatment/cancer-medications/medication-safety/box-warnings
41. 213591Orig1s000 - accessdata.fda.gov, accessed August 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213591Orig1s000RiskR.pdf
42. Capmatinib Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 21, 2025, https://www.drugs.com/dosage/capmatinib.html
43. Capmatinib: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 21, 2025, https://www.rxlist.com/capmatinib/generic-drug.htm
44. Capmatinib Uses, Side Effects & Warnings - Drugs.com, accessed August 21, 2025, https://www.drugs.com/mtm/capmatinib.html
45. 1 Tradename 2 Description and composition 3 Indications 4 Dosage ..., accessed August 21, 2025, https://www.novartis.com/sg-en/sites/novartis_sg/files/Tabrecta-Mar2021.SIN-App221021.pdf
46. Tabrecta Interactions: Other Medications, Alcohol, and More - Healthline, accessed August 21, 2025, https://www.healthline.com/health/drugs/tabrecta-interactions
47. Tabrecta and Alcohol/Food Interactions - Drugs.com, accessed August 21, 2025, https://www.drugs.com/food-interactions/capmatinib,tabrecta.html
48. Capmatinib Interactions Checker - Drugs.com, accessed August 21, 2025, https://www.drugs.com/drug-interactions/capmatinib.html
49. FDA Approves Capmatinib Tablets for Metastatic NSCLC, accessed August 21, 2025, https://www.accc-cancer.org/state-societies/Arizona/corporate-members/industry-news/fda-approves-capmatinib-tablets-for-metastatic-nsclc
50. Part 4: Whether to Switch Treatments After Discovery of MET Mutations in NSCLC, accessed August 21, 2025, https://www.targetedonc.com/view/part-4-whether-to-switch-treatments-after-discovery-of-met-mutations-in-nsclc
51. Part 2: Choosing a Treatment for NSCLC with MET Exon 14 Skipping Mutation, accessed August 21, 2025, https://www.targetedonc.com/view/part-2-choosing-a-treatment-for-nsclc-with-met-exon-14-skipping-mutation
52. FDA approves tepotinib for metastatic non-small cell lung cancer, accessed August 21, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tepotinib-metastatic-non-small-cell-lung-cancer
53. View of First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression - AboutScience, accessed August 21, 2025, https://journals.aboutscience.eu/index.php/dti/article/view/2626/3126
54. FDA Approves TEPMETKO for Metastatic NSCLC | ACCP, accessed August 21, 2025, https://accp1.org/members/ACCP1/5Publications_and_News/FDABurst2021/TEPMETKO-Metastatic-NSCLC.aspx
55. MET targeted therapy in non-small cell lung cancer patients with ..., accessed August 21, 2025, https://tlcr.amegroups.org/article/view/85336/html
56. Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells - OmicsDI, accessed August 21, 2025, https://www.omicsdi.org/dataset/geo/GSE94405
57. SNU Open Repository and Archive: Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells - S-Space - 서울대학교, accessed August 21, 2025, https://s-space.snu.ac.kr/handle/10371/132316
58. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/30309221/
59. MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report - Translational Lung Cancer Research, accessed August 21, 2025, https://tlcr.amegroups.org/article/view/67944/html